The Role of Biomarkers in Hepatitis B Management
Is Hepatitis B entering the era of personalised medicine?
Watch the recording:
New cure strategies for Hepatitis B are in development. Emerging data suggest a key role for biomarkers to identify subsets of people living with Hepatitis B who are most likely to respond to treatment.
In this webinar, we discussed recent advances in Hepatitis B biomarker development, and how these tools can be used to personalise the management of people living with Hepatitis B.
Who should attend:
- Infectious disease clinicians
- Pathologists
- Trainee physicians
- Gastroenterologists
- Medical scientists
Reasons to attend:
- To learn about the latest advances in the management of Hepatitis B
- To understand the clinical value of biomarkers in the management of Hepatitis B
- To know the clinical approach to managing patients with Hepatitis B
- To be aware of the guidelines on the usage of Hepatitis B markers
- To hear from Infectious Disease clinicians about the potential of RUO biomarkers in real-world clinical practice
Faculty
Associate Professor Mark Douglas, BSc (Med)(Hons), MBBS (Hons), PhD, FRACP
Associate Professor, Storr Liver Centre
Research Academic Director - Clinical Science
The Westmead Institute for Medical Research,
The University of Sydney Westmead Clinical School
Faculty of Medicine and Health
Professor Alex Thompson, MBBS (hons), PhD, FRACP, FGESA, FAASLD, GAICD
Director of Gastroenterology, St. Vincent’s Hospital Melbourne
University of Melbourne
© 2023 Roche Diagnostics
Roche Diagnostics Australia Pty Limited ABN 29 003 001 205
2 Julius Avenue North Ryde NSW 2113 Australia Phone: 02 9860 2222